Viewing Study NCT05767047



Ignite Creation Date: 2024-05-06 @ 6:44 PM
Last Modification Date: 2024-10-26 @ 2:53 PM
Study NCT ID: NCT05767047
Status: RECRUITING
Last Update Posted: 2024-05-16
First Post: 2023-03-08

Brief Title: A Study of Apremilast in Children With Oral Ulcers Associated With Behçets Disease or Juvenile Psoriatic Arthritis
Sponsor: Amgen
Organization: Amgen

Study Overview

Official Title: A Phase 3 Multicenter Open-label Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçets Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis
Status: RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of this study is to evaluate the long-term safety of apremilast in participants 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2022-003024-41 EUDRACT_NUMBER None None